乳癌モノクローナル抗体(mAbs)の世界市場2016-2020

◆英語タイトル:Global Breast Cancer Monoclonal Antibodies Market 2016-2020
◆商品コード:IRTNTR10205
◆発行会社(調査会社):Technavio
◆発行日:2016年9月6日
◆ページ数:88
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥285,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥342,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥456,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。



当調査レポートでは、乳癌モノクローナル抗体(mAbs)の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、乳癌モノクローナル抗体(mAbs)の世界市場規模及び予測、種類別分析、需要先別分析、地域別分析/市場規模、購買基準、市場の成長要因、市場の課題、市場動向、競争状況などの情報をお届けいたします。
【レポートの概要】

About Breast Cancer mAbs
Breast cancer is characterized by the malignancy of cells in the tissues of the breast. HER-2 breast cancer is the most common type of breast cancer. The HER-2 protein, present on the surface of normal breast cells, affects the growth of the malignant cells. The uncontrolled synthesis of this protein stimulates the growth and division of malignant cells. Antibodies are the proteins produced by B-cells (in the bone marrow) in the immune system. These proteins attach themselves to antigens, which act as markers, and are then destroyed by phagocytes. B-cells produce different antibodies, which attach themselves to different sites of an antigen. mAbs are monospecific, as they are the clones of a single parent cell.

Technavio’s analysts forecast the global breast cancer monoclonal antibodies (mAbs) market to post a revenue of 13.7 billion by 2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global breast cancer monoclonal antibodies (mAbs) market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sale of branded mAbs and biosimilars used to treat breast cancer.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Breast Cancer Monoclonal Antibodies (mAbs) Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Amgen
• Roche
• Mylan

[Other prominent vendors]
• Array BioPharma
• AstraZeneca
• Biocad
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Celldex Therapeutics
• Celltrion
• Chugai Pharmaceutical
• Daiichi Sankyo
• DARA Biosciences
• Eddingpharm
• Eisai
• Galena Biopharma
• GlaxoSmithKline
• Halozyme Therapeutics
• Hospira
• ImmunoGen
• Immunomedics
• MacroGenics
• Merck
• Novartis
• Oncothyreon
• Pfizer
• ProStrakan
• Puma Biotechnology
• Seattle Genetics
• Sun Pharmaceutical Industries
• Synta Pharmaceuticals
• Teva Pharmaceuticals

[Market driver]
• Reimbursement benefits for breast cancer mAbs
• For a full, detailed list, view our report

[Market challenge]
• Absence of adequate diagnosis and screening procedures for early detection
• For a full, detailed list, view our report

[Market trend]
• Emergence of targeted and combination therapies for breast cancer
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Assumptions
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Breast cancer: Overview
• Understanding the disease
• Treatment regimen for breast cancer
• Overview of mAbs

PART 06: Pipeline portfolio

PART 07: Market landscape
• Market overview
• Five forces analysis

PART 08: Market segmentation by type of mAbs
• Naked mAbs
• Conjugated mAbs

PART 09: Market segmentation by end-user
• Hospitals
• Retail pharmacies

PART 10: Geographical segmentation
• Global breast cancer mAbs market by geographical segmentation 2015-2020
• Breast cancer mAbs market in Americas
• Breast cancer mAbs market in EMEA
• Breast cancer mAbs market in APAC

PART 11: Market drivers
• Reimbursement benefits for breast cancer mAbs
• Increase in demand for breast cancer ADCs
• Huge market potential for breast cancer mAbs owing to product approvals
• Exposure to risk factors

PART 12: Impact of drivers

PART 13: Market challenges
• Absence of adequate diagnosis and screening procedures for early detection
• High manufacturing costs coupled with stringent regulations
• Threat from chemotherapy and off-label drugs
• Difficulties in patient recruitment for conducting clinical trials

PART 14: Impact of drivers and challenges

PART 15: Market trends
• Emergence of targeted and combination therapies for breast cancer
• Growing focus of vendors on untapped markets
• Emergence of biosimilars
• Outsourcing of biosimilar manufacturing activities
• Need for high investment in R&D

PART 16: Vendor landscape
• Competitive scenario
• Key news
• Roche
• Amgen
• Mylan
• Other prominent vendors

PART 17: Appendix
• List of abbreviations

PART 18: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Global breast cancer mAbs market snapshot
Exhibit 03: Key buying criteria for breast cancer mAbs 2015
Exhibit 04: Impact of key customer segments on market 2015
Exhibit 05: Breast cancer stages based on tumor size and extent of metastasis
Exhibit 06: Classification of breast cancer based on genetic make-up of tumor cells
Exhibit 07: Treatment regimen for breast cancer
Exhibit 08: Comparison of small molecules and mAbs
Exhibit 09: Preparation of mAbs
Exhibit 10: Global breast cancer mAbs market: Key metrics analysis snapshot
Exhibit 11: Global breast cancer mAbs market: Pipeline snapshot 2015
Exhibit 12: Pipeline portfolio: Global breast cancer mAbs market 2015
Exhibit 13: Developmental history of trastuzumab biosimilars in various countries
Exhibit 14: Global breast cancer mAbs market snapshot: Developed and emerging markets 2015
Exhibit 15: Global breast cancer mAbs market 2015-2020 ($ billions)
Exhibit 16: Factors influencing global breast cancer mAbs market 2015
Exhibit 17: Timeline for development of breast cancer mAbs
Exhibit 18: Impact of drivers and challenges of global breast cancer mAbs market
Exhibit 19: Five forces analysis
Exhibit 20: Approved naked mAbs by US FDA and EU
Exhibit 21: Global breast cancer mAbs market segmentation by type of molecule 2015
Exhibit 22: Global breast cancer mAbs market segmentation by end-user 2015
Exhibit 23: Global breast cancer mAbs market: Geographical outlook 2015-2020
Exhibit 24: Global breast cancer mAbs market: Geographical outlook 2015
Exhibit 25: Revenue/growth outlook in different countries/regions 2015
Exhibit 26: Global breast cancer mAbs market segmentation by region: Market growth lifecycle analysis 2015
Exhibit 27: Opportunity analysis of breast cancer mAbs market in Americas
Exhibit 28: Breast cancer mAbs market in Americas 2015-2020 ($ billions)
Exhibit 29: Breast cancer mAbs market in Americas by country 2015
Exhibit 30: Opportunity analysis of breast cancer mAbs market in EMEA
Exhibit 31: Breast cancer mAbs market in EMEA 2015-2020 ($ billions)
Exhibit 32: Opportunity analysis of breast cancer mAbs market in APAC
Exhibit 33: Number of individuals treated with Herceptin through patient assistance programs in China 2011-2014
Exhibit 34: Breast cancer mAbs market in APAC 2015-2020 ($ billions)
Exhibit 35: Global breast cancer mAbs market revenue by geography 2015-2020 ($ billions)
Exhibit 36: Impact of drivers
Exhibit 37: Five-year survival rate by stage of diagnosis
Exhibit 38: Impact of drivers and challenges
Exhibit 39: Global breast cancer mAbs market: Impact assessment of key trends
Exhibit 40: Competitive assessment of vendors
Exhibit 41: Key vendors: Geographical presence 2015
Exhibit 42: Roche: YoY growth and revenue generated from net product sales of Avastin 2013-2015 ($ billions)
Exhibit 43: Roche: Geographical segmentation of Avastin by revenue 2015
Exhibit 44: Roche: YoY growth and revenue generated from net product sales of Herceptin 2013-2015 ($ billions)
Exhibit 45: Roche: Geographical segmentation of Herceptin 2015
Exhibit 46: Roche: YoY growth and revenue generated from net product sales of Perjeta 2013-2015 ($ billions)
Exhibit 47: Roche: Geographical segmentation of Perjeta 2015
Exhibit 48: Roche: Revenue generated from net product sales of Kadcyla 2013-2015 ($ millions)
Exhibit 49: Roche: Geographical segmentation of Kadcyla 2015
Exhibit 50: Roche: Metrics analysis
Exhibit 51: Amgen: YoY growth and revenue generated from net product sales of Xgeva 2013-2015 ($ billions)
Exhibit 52: Amgen: Geographical segmentation of Xgeva 2015
Exhibit 53: Amgen: Metrics analysis
Exhibit 54: Mylan: Business segmentation by revenue 2015
Exhibit 55: Mylan: Geographical segmentation by revenue 2015 (generics segment)
Exhibit 56: Mylan: Metrics analysis



【掲載企業】

Roche, Amgen, Mylan, Actavis, Array BioPharma, AstraZeneca, Biocad, Boehringer Ingelheim, Bristol-Myers Squibb, Celldex Therapeutics, Celltrion, Chugai Pharmaceutical, Daiichi Sankyo, DARA Biosciences, Eddingpharm, Eisai, Galena Biopharma, GlaxoSmithKline, Halozyme Therapeutics, Hospira, ImmunoGen, Immunomedics, MacroGenics, Merck, Novartis, Oncothyreon, Pfizer, ProStrakan, Puma Biotechnology, Seattle Genetics, Sun Pharmaceutical Industriesf, Synta Pharmaceuticals, Teva Pharmaceuticals.


【レポートのキーワード】

乳癌、モノクローナル抗体(mAbs)、治療薬

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[乳癌モノクローナル抗体(mAbs)の世界市場2016-2020]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。
※当サイトでは2016年12月07日現在 219,203 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆